Skip to main content
. 2018 May 10;2018(5):CD012069. doi: 10.1002/14651858.CD012069.pub2

Aguilera‐Albesa 2010.

Methods 2 patient reports of the appearance of hallucinations few hours after methylphenidate ingestion
Participants Case 1
Diagnosis of ADHD: DSM‐IV (subtype: inattentive)
Age: 8 years old
IQ: > 85
Sex: male
Methylphenidate naïve: not stated
Ethnicity: white
Country: Spain
Comorbidity: procedural learning disorder
Comedication: not stated
Sociodemographics: not stated
Case 2
Diagnosis of ADHD: DSM‐IV (subtype: inattentive)
Age: 6 years old
IQ: > 85
Sex: female
Ethnicity: white
Country: Spain
Comorbidity: none
Comedication: none
Sociodemographics: not stated
Interventions Case 1
Extended release methylphenidate 18 mg/day (0.51 mg/kg/day)
Administration schedule: once daily
Duration of intervention: 2 days
Treatment compliance: not stated
Case 2
50% extended release, and 50% immediate release methylphenidate 10 mg/day (0.45 mg/kg/day) for 3 days and 20 mg/day (0.9 mg/kg/day) for 1 day
Administration schedule: once daily
Duration of intervention: 4 days
Treatment compliance: not stated
Outcomes Serious adverse events:
 Case 1
After the first dose: irritability, emotional lability, motor restlessness and facial motor tics
After the second dose: added auditory hallucinations (noise and unintelligible verbal expressions), and visual hallucinations (shadows approaching and receding)
24 hours after discontinuation: the symptoms remitted
Case 2
After the first dose and the following days: intermittent visual hallucinations (insects, especially flies, flying around her). The symptoms improved at night
After increased dose (20 mg) on day 4: visual hallucinations were associated with dread of going outside and cries of panic
1 day after discontinuation: the symptoms remitted
Notes Key conclusions of the study authors: these patient reports suggest an individual susceptibility to psychotic symptoms after taking methylphenidate. This side effect is considered idiosyncratic, extraordinary and unpredictable. Case 2 suggests the existence of a dose‐effect relationship
Supplemental information regarding diagnostic criteria and IQ received through personal email correspondence with the authors in July 2013 (Aguilera‐Albesa 2013 [pers comm])